Seborrhoeic dermatitis: Pathogenetic, clinical and therapeutic aspects;Łojotokowe zapalenie skóry: Aspekty patogenezy, kliniki i terapii

Dermatologia Kliniczna

Volumn 8, Issue 2, 2006, Pages 127-131

  Salomon, Joanna ^a   Szepietowski, Jacek ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Pathogenesis; Seborrhoeic dermatitis; Treatment

Indexed keywords

CALCINEURIN INHIBITOR; CICLOPIROX; SHAMPOO; TACROLIMUS;

CLINICAL FEATURE; CREAM; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; ENDOCRINE DISEASE; HUMAN; MALASSEZIA; PATHOGENESIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SCALP; SEBACEOUS GLAND; SEBORRHEIC DERMATITIS; SKIN DEFECT; SKIN DISEASE; SKIN INFLAMMATION;

EID: 33745833675     PISSN: 17307201     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Gupta A.K., Bluhm R.: Seborrhoeic dermatitis. J. Eur. Acad. Dermatol. Venereol., 2004, 18, 13-26.
2. Gupta A.K., Madzia S.E., Batra R.: Etiology and management of seborrhoeic dermatitis. Dermatology, 2004, 208, 89-93.
3. Gupta A.K., Nicol K., Batra R.: Role of antifungal agents in the treatment of seborrhoeic dermatitis. Am. J. Clin. Dermatol., 2004, 5, 417-422.
4. Kołodziej T., Białynicki-Birula R.: Łojotokowe zapalenie skóry - poważny problem dermatologiczny. Dermatol. Klin. Zabieg., 1999, 1, 95-98.
5. Bergbrant I.M., Faergemann J.: Seborrhoeic dermatitis and Pityrosporum ovale: a cultural and immunological study. Acta Derm. Venereol. (Stockh.), 1989, 69, 332-335.
6. Heng M.C.Y., Henderson C.L., Barker D.C., Haberfelde G.: Correlation of Pityrosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J. Am. Acad. Dermatol., 1990, 23, 82-86.
7. Gupta A.K., Kohli Y., Summerbell R.C., Faergemann J.: Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med. Mycol., 2001, 39, 243-251.
8. Nakabayashi A., Sei Y., Guillot J.: Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis veriscolor and normal subjects. Med. Mycol., 2000, 38, 337-341.
9. Sandström M.H., Bartosik J., Bǎck O.: The prevalence of the Malassezia yeasts in patients with atopic dermatitis, seborrhoeic dermatitis and healthy controls. J. Eur. Acad. Dermatol. Venereol., 2001, 15, Suppl. 2, 104-274.
10. Bergbrant I.M., Johansson S., Robbins D., Scheynius A., Faergemann J., Soderstrom T.: An immunological study in patients with seborrhoeic dermatitis. Clin. Exp. Dermatol., 1991, 16, 331-338.
11. Faergemann J., Bergbrant I.M., Dohse M., Scott A., Westgate G.: Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterisation of inflammatory cells and mediators in the skin by immunohistochemistry. Br. J. Dermatol., 2001, 144, 549-556.
12. Ilchyshyn A., Mendelson S.S., Macfarlane A., Verbov J.: Candida albicans and infantile seborrhoeic dermatitis. Br. J. Clin. Pract., 1987, 41, 557-559.
13. Tollesson A., Frithz A., Berg A., Karlman G.: Essential fatty acids in infantile seborrhoeic dermatitis. J. Am. Acad. Dermatol., 1993, 28, 957-961.
14. Nisenson A., Barness L.A.: Treatment of seborrheic dermatitis with biotin and vitamin B complex. J. Pediatr., 1972, 8, 630-631.
15. Szepietowski J., Salomon J.: Łojotokowe zapalenie skóry: aspekty patogenezy, kliniki i terapii. [w:] Wybrane zagadnienia z praktyki lekarza rodzinnego. Tom 7. red. A. Steciwko. Continuo 2006, [w druku].
16. Alessi E., Cusini M., Zerboni R.: Mucocutaneous manifestations in patients infected with human immunodeficiency virus. J. Am. Acad. Dermatol., 1988, 19, 290-297.
17. Szybejko-Machaj G.: Choroby gruczołów łojowych. [w:] Leczenie chorób skóry i chorób przenoszonych droga̧. płciowa̧. red. J. Szepietowski. PZWL, Warszawa, 2002, 399-418.
18. Hay R.J., Graham-Brown R.A.: Dandruff and seborrhoeic dermatitis: causes and management. Clin. Exp. Dermatol., 1997, 22, 1-3.
19. Kołodziej T., Białynicki-Birula R.: Cyklopiroks w leczeniu łojotokowego zapalenia skóry. Mikol. Lek., 2004, 11, 329-332.
20. Rosen T., Schell B.J., Orengo I.: Anti-inflammatory activity of antifungal preparations. Int. J. Dermatol., 1997, 36, 788-792.
21. Unholzer A., Varigos G., Nicholls D., Schinzel S., Nietsch K.H., Ulbricht H., Korting H.C.: Ciclopiroxolamine cream for treating seborrhoeic dermatitis: a double-blind parallel group comparison. Infection, 2002, 30, 373-376.
22. Unholzer A., Schinzel S., Nietsche K.H., Jung G.E., Korting H.C.: Ciclopiroxolamine cream 1% in the treatment of seborrhoeic dermatitis: a double-blind, parallel-group comparison with ketokonazole and vehicle in a confirmatory trial. Clin. Drug. Invest., 2002, 22, 167-172.
23. Chosidow O., Maurette C., Dupuy P.: Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketokonazole 2% foaming gel in mild to moderate facial seborrhoeic dermatitis. Dermatology, 2003, 3, 233-240.
24. Altmayer P., Hoffmann K.: Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrhoeic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial. Int J. Dermatol., 2004, 43, Suppl. 1, 9-12.
25. Abeck D.: Loprox Shampoo Dosing study Group: Rationale of frequency of use of ciclopirox 1% shampoo in the treatment of seborrhoeic dermatitis: results of a double-blind, placebo-controlled study comparing the efficacy of once, twice, and three times weekly usage. Int J. Dermatol., 2004, 43, Suppl. 1, 13-16.
26. Lebwohl M., Plott T.: Safety and efficacy of ciclopirox 1% shampoo for the treatment of seborrhoeic dermatitis of the scalp in the US population: results of a double-blind, vehicle-controlled trial. Int. J. Dermatol., 2004, 43, Suppl. 1, 17-20.
27. Shuster S., Meynadier J., Kerl H., Nolting S.: Treatment and prophylaxis of seborrhoeic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch. Dermatol., 2005, 141, 47-52.
28. th World Congress of Dermatology, 2002, Paris, France, Abstract P1662.
29. st Annual Meeting of the American Academy of Dermatology, 2003, San Francisco, USA, Abstract P165.
30. st Annual Meeting of the American Academy of Dermatology, 2003, San Francisco, USA, Abstract P90.
31. Rigopoulos D., ioannides D., Kalogeromitros D., Gregoriou S., Katsambas A.: Pimecrolimus cream 1% vs betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br. J. Dermatol., 2004, 151, 1071-1075.
32. Crutchfield C.E.: A new treatment for seborrheic dermatitis. Cutis, 2002, 70, 207-208.
33. Białynicki-Birula R., Szepietowski J., Kołodziej T.: Skuteczność miejscowo stosowanego pimekrolimusu w leczeniu łojotokowego zapalenia skóry ze zmianami na twarzy. XXVIII Zjazd Poiskiego Towarzystwa Dermatologicznego, Bydgoszcz 2004, Abstrakt P28.
34. Darves B.: Comparison of pimecrolimus cream 1% and tacrolimus ointment 0.03% in pediatric patients with atopic eczema. J. Eur. Acad. Dermatol. Venereol., 2003; Abstracts: Poster Presentation 2.41.
35. Kempers S., Boguniewicz M., Carter E., Jarratt M., Pariser D., Stewart D., Stiller M., Tschen E., Chon K., Wisseh S., Abrams B.: A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J. Am. Acad. Dermatol., 2004, 51, 515-525.
36. Brownell J., Quan L.T., Hsu S.: Topical pimecrolimus in the treatment of seborrhoeic dermatitis. Dermatol. Online J., 2003, 9, 13.
37. Faergemann J.: Management of seborrheic dermatitis and pityriasis versicolor. Am. J. Clin. Dermatol., 2000, 1, 75-80.
38. Caputo R., Barbareschi M.: Itraconazole: new horizons. G. Ital. Dermatol. Venereol., 2002, 137, 1-7.